Medical Management References:

​

1.         Zar, F.A., et al., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis, 2007. 45(3): p. 302-7.

​

2.         Johnson, S., et al., Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis, 2014. 59(3): p. 345-54.

 

3.         Cornely, O.A., et al., Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a

double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis, 2012. 12(4): p. 281-9.

 

4.         Louie, T.J., et al., Fidaxomicin versus Vancomycin for Clostridium difficile Infection. New England Journal of Medicine, 2011. 364(5): p. 422-431.

 

5.         Goldenberg, S.D., et al., The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis, 2016. 35(2): p. 251-9.

 

6.         McDonald, L.C., et al., Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the

Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 2018.

​